| Michael E Theodorakis, MD | |
|
235 N Belle Mead Rd, E Setauket, NY 11733-3456 | |
| (631) 751-3000 | |
| (631) 751-3366 |
| Full Name | Michael E Theodorakis |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Hematology & Oncology |
| Location | 235 N Belle Mead Rd, E Setauket, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467456806 | NPI | - | NPPES |
| 01415838 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 137427 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Michael E Theodorakis, MD 235 N Belle Mead Rd, E Setauket, NY 11733-3456 Ph: (631) 751-3000 | Michael E Theodorakis, MD 235 N Belle Mead Rd, E Setauket, NY 11733-3456 Ph: (631) 751-3000 |
News Archive
End-stage heart failure patients treated with stem cells harvested from their own bone marrow experienced 37 percent fewer cardiac events - including deaths and heart failure hospital admissions - than a placebo-controlled group, according to a new study.
Obtaining therapy via teleconference is just as effective as face-to-face sessions, according to a new research by St-phane Guay, a psychiatry professor at the Universit- de Montr-al.
Stimulating the visual cortex of the brain for 20 minutes with a mild electrical current can improve vision for about two hours, and those with worse vision see the most improvement, according to a Vanderbilt University study published this week in Current Biology.
TxCell SA, a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells to treat severe chronic inflammatory and autoimmune diseases, today announces the signature of a strategic R&D collaboration agreement with the Lübeck Institute of Experimental Dermatology, a leading institution in the field of translational research on skin blistering diseases, part of the University of Lübeck in Germany.
A study led by The University of Texas MD Anderson Cancer Center showed that treatment combining lower doses of chemotherapy with the monoclonal antibody inotuzumab ozogamicin (INO), with or without the drug blinatumomab, is safe and effective in patients over 60 years of age who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative ALL.
› Verified 1 days ago
Dr. Allen Jeremias, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 26 Research Way, E Setauket, NY 11733 Phone: 631-444-0580 | |
Diane M Clausen, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 235 N Belle Mead Rd, E Setauket, NY 11733 Phone: 631-751-3000 Fax: 631-675-2001 | |
Edward T Samuel, MD, PHD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 235 N Belle Mead Rd, E Setauket, NY 11733 Phone: 631-751-3000 Fax: 631-751-3366 | |
Gurmohan Syali, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 235 N Belle Mead Rd, E Setauket, NY 11733 Phone: 631-751-3000 Fax: 631-751-3366 |